Recurrent vaginal yeast infection: 8 guidelines compared

This narrative review compared eight selected guidelines. Two define recurrent vulvovaginal candidiasis (VVC) as at least three symptomatic episodes in a year; six use at least four. It adds no clinical outcome data or treatment or safety finding, so it does not change practical guidance.

The review makes differences in recurrence thresholds and confirmation language visible. Its proposed distinction between vaginal disease and vulvar skin disease remains a conceptual framework, not a validated classification.

This is a narrative and conceptual review of eight selected guidelines and cited literature, not a study that recruited participants. The populations discussed come from heterogeneous cited sources; the review has no single participant cohort.

The authors compared guideline definitions and descriptions of recurrent VVC and proposed two phenotypes: estrogen-dependent vaginal VVC and estrogen-independent vulvar cutaneous candidiasis. This is the review authors' proposed framework; it has not been validated or uniformly adopted.

Among the eight selected guidelines, CDC and ISSVD use a threshold of at least three symptomatic episodes per year; the other six use at least four. The review also describes variation in confirmation requirements.

For ISSVD, Table 1 lists microscopy, culture, or NAAT as options without an explicit requirement. The surrounding prose says that a positive culture is crucial before therapy. The authors do not reconcile this table/prose discrepancy, so the review does not establish one universal test rule.

There is no primary participant cohort, pooled or comparative clinical outcome, or clinical treatment or safety finding in this review. It reports no absolute clinical outcome estimate with a denominator.

The review can help readers understand why selected guidelines describe recurrence and confirmation differently. Its proposed estrogen-dependent vaginal versus estrogen-independent vulvar cutaneous distinction is an author-proposed framework, not a validated way to classify an individual person's symptoms.

The article reports no systematic search methods, screening flow, or formal risk-of-bias assessment. Its eight selected guidelines are heterogeneous and are not a complete global inventory. The proposed phenotype distinction has not been validated, and the review has no primary cohort or comparative outcome data to establish prognosis, treatment effects, or safety.

Contextual contribution. The review documents variation in guideline definitions and confirmation descriptions, but does not change the broader evidence map or establish a new diagnostic classification.

No practical change. This review does not establish a new universal episode threshold, confirmation rule, diagnosis, treatment choice, or safety action.

The authors reported that the work received no funding and declared no conflict of interest.

Read the original publication (published 28 May 2025; issue date 12 June 2025).